-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 27, 2021, Innovent and Bolt Biotherapeutics jointly announced that the two parties have reached a new drug research and development cooperation agreement to jointly develop three antibody-immunostimulatory conjugate (ISAC) drug candidates for the treatment of cancer
.
The two parties will combine Cinda's proprietary antibody drug portfolio and R&D capabilities for undisclosed tumor targets, and Bolt's advanced ISAC technology and expertise in the field of myeloid cells to jointly develop three new anti-cancer immunotherapy drugs, which are expected to provide patients Bring significant benefits
.
Bolt's ISAC technology platform combines the accuracy of antibody targeting with the role of stimulating innate and adaptive immune system responses
.
It consists of three main components: tumor-targeting antibodies, stable and non-degradable linkers, and proprietary immunostimulants used to activate the patient's innate immune system
ISAC can activate and recruit bone marrow cells to generate new immune responses
.
The activated bone marrow cells will release cytokines and chemokines, attract other immune cells and reduce the chemical signal of the activation threshold of the immune response, and start the feedforward cycle
▲ Bolt’s ISAC can activate a variety of immune cells (picture source: Bolt’s official website)
According to the terms of the agreement, Cinda Bio will have the rights to the Greater China region of the three cooperative projects, while retaining the global rights of one of the projects and the right to choose the rights of the other project in regions other than North America
.
Bolt reserves the right to choose the regional rights for one of the projects except Greater China and the North American regional rights for the other project
Bolt will receive a down payment of US$5 million from Cinda Bio, and a potential equity investment of up to US$10 million in the future
.
In addition, both companies are eligible to receive corresponding milestone payments and royalties
Reference materials:
[1] Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs.
